Market closed

Amgen/$AMGN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Ticker

$AMGN

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Thousand Oaks, United States

Employees

26,700

Website

www.amgen.com

Amgen Metrics

BasicAdvanced

$145B

34.49 $7.83

0.60 $9.00

3.52%

Price and volume

Market cap

$145B

Beta

0.6

52-week high

$346.85

52-week low

$253.30

Average daily volume

3.8M

Dividend rate

$9.00

Financial strength

Current ratio

1.318

Quick ratio

0.804

Long term debt to equity

755.334

Total debt to equity

802.418

Dividend payout ratio (TTM)

112.70%

Interest coverage (TTM)

2.07%

Management effectiveness

Return on assets (TTM)

4.60%

Return on equity (TTM)

55.72%

Valuation

Price to earnings (TTM)

34.494

Price to revenue (TTM)

4.456

Price to book

19.29

Price to tangible book (TTM)

-3.63

Price to free cash flow (TTM)

23.071

Dividend yield (TTM)

3.33%

Forward dividend yield

3.52%

Growth

Revenue change (TTM)

21.25%

Earnings per share change (TTM)

-44.29%

3-year revenue growth (CAGR)

8.08%

3-year earnings per share growth (CAGR)

-6.88%

3-year dividend per share growth (CAGR)

8.88%

What the Analysts think about Amgen

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Amgen stock.

Amgen Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Amgen Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Amgen News

AllArticlesVideos

Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)

Seeking Alpha·1 day ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Seeking Alpha·1 day ago

Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)

Seeking Alpha·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMGN

$

Capital at risk

Market closed

Upcoming events

Feb14

Amgen

Dividend·Ex-dividend

Mar7

Amgen

Dividend·Payment

$2.38

Per share

FAQs

What’s the current market cap for Amgen stock?

Amgen (AMGN) has a market cap of $145B as of January 15, 2025.

What is the P/E ratio for Amgen stock?

The price to earnings (P/E) ratio for Amgen (AMGN) stock is 34.49 as of January 15, 2025.

Does Amgen stock pay dividends?

Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of January 15, 2025, the dividend rate is $9 and the yield is 3.52%. Amgen has a payout ratio of 112.7% on a trailing twelve-month basis.

When is the next Amgen dividend payment date?

The next Amgen (AMGN) dividend payment is scheduled for March 07, 2025.

What is the beta indicator for Amgen?

Amgen (AMGN) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.